Discontinuation of antihypertensive drugs appears to have a detrimental effect, with a recent study reporting that the risk of acute myocardial infarction (AMI) substantially increases after more than 90 days of discontinuation.

Prediagnostic statin exposure appears to be associated with a significant reduction in breast cancer-specific mortality, with the survival benefit being more pronounced in women with oestrogen receptor (ER)-positive tumours, according to a study.

ENABLEX Now Approved in Malaysia

22 May 2015

Reclassification of MIMS Class – ENABLEX
In MIMS 140th edition (1st Issue 2015), there was an error classifying Enablex under
10f. Other Drugs Acting on the Genito-Urinary System. With effect from MIMS 141st edition (2nd
Issue 2015), Enablex will be reclassified under 10e. Drugs for Bladder & Prostate Disorder
to reflect a more accurate classification based on its therapeutic use.

ENABLEX – Darifenacin Hydrobromide 7.5mg Prolonged Release Tablet• A highly selective M3 antagonist developed for treating overactive bladder (OAB)
1, 2• Improves Incontinence Episodes (IEs) per week, Urgency Episodes (UEs) per day and micturitions per day in OAB patients with 5-50 episodes of incontinence per week
3• No significant effect on heart rate 4• Does not prolong the QT/QTc interval 5• Does not impair memory or other cognitive functions 6

Discontinuation of antihypertensive drugs appears to have a detrimental effect, with a recent study reporting that the risk of acute myocardial infarction (AMI) substantially increases after more than 90 days of discontinuation.

Prediagnostic statin exposure appears to be associated with a significant reduction in breast cancer-specific mortality, with the survival benefit being more pronounced in women with oestrogen receptor (ER)-positive tumours, according to a study.